September deadline for global clinical investigations posted
This article was originally published in Clinica
Executive Summary
Study Group 5 of the Global Harmonization Task Force has posted on its website a new proposed document, SG5(PD)N37, concerning clinical investigations. The deadline for comments is September 14 2008. The text is accompanied by a comment template. The document covers issues including: general principles when considering the need for a clinical investigation; general principles of clinical investigation design; and ethical considerations for clinical investigations. It is 11 pages long and only applies to clinical investigations of medical devices, and not diagnostics. Some aspects of this document may apply to studies conducted following commercial release of a device. Future GHTF documents will specifically address post-market follow-up studies.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.